Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Longeveron (NASDAQ:LGVN) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Longeveron’s Q4 2024 earnings at ($0.40) EPS, FY2024 earnings at ($2.83) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.46) EPS.

Separately, Maxim Group dropped their price target on shares of Longeveron from $15.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 27th.

Longeveron Trading Up 3.0 %

Longeveron stock opened at $2.06 on Monday. The stock has a market capitalization of $30.56 million, a price-to-earnings ratio of -0.33 and a beta of 0.36. The stock has a 50 day moving average of $2.02 and a two-hundred day moving average of $2.13. Longeveron has a twelve month low of $0.77 and a twelve month high of $23.90.

Longeveron (NASDAQ:LGVN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.19. The firm had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.34 million. Longeveron had a negative return on equity of 142.43% and a negative net margin of 967.49%. During the same period last year, the company earned ($2.80) earnings per share. Equities analysts predict that Longeveron will post -3.72 earnings per share for the current year.

Institutional Trading of Longeveron

Institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new stake in Longeveron in the second quarter valued at $236,000. Geode Capital Management LLC grew its stake in shares of Longeveron by 316.0% during the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock worth $250,000 after purchasing an additional 97,953 shares during the period. Finally, State Street Corp purchased a new position in shares of Longeveron in the 3rd quarter valued at about $29,000. 10.01% of the stock is currently owned by hedge funds and other institutional investors.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.